Skip to main content
Bild

News categories: Publication

Focus on the Guardians of the Antibody Response

For the immune system to effectively combat pathogens, antibody responses must be precisely controlled. So-called follicular regulatory T cells (Tfr cells) play a key role in this process by limiting excessive immune responses and helping to maintain immune tolerance. Researchers at the University Hospital Bonn (UKB) and the University of Bonn have now developed a robust laboratory method that allows Tfr cells to be generated from precursor cells and studied in a targeted manner. The results were recently published in the journal Cellular & Molecular Immunology. 

 

Tfr cells control the development and function of so-called germinal centers in lymphoid organs such as the lymph nodes, tonsils, or spleen. There, they regulate the activity of follicular T helper cells (Tfh cells) and B cells, ensuring that antibody responses remain effective without getting out of control. An imbalance between activating and regulatory immune cells is associated with autoimmune diseases and misdirected antibody responses.

“Tfr cells have been difficult to study until now. With our model, we can now specifically track their development in the laboratory and investigate the molecular mechanisms that control their properties and functions,” says first author Dr. Luisa Bach, scientist at the University Hospital Bonn. 

How follicular regulatory T cells develop 

For their research, the scientists developed a new in vitro model that allows Tfr cells to be generated from certain CD4+ T helper cells of the immune system. Using this system, they were able to identify key molecular signaling pathways that control the development of these cells.

It turned out that the growth factor TGF-β plays a key role: It is both necessary and sufficient to trigger the characteristic program of Tfr cells. At the same time, the signaling molecule IL-2 influences the development of the cells in an opposing manner. Only the finely tuned interaction of both signaling pathways enables the formation of functional Tfr cells.

Furthermore, the research team identified the transcription factor c-Maf as an important regulator of the differentiation of Tfr cells. If this factor is absent, the cells cannot fully develop the characteristics typical of Tfr cells.

Immunofluorescence image showing T cells (red), B cells (green), and IgG1-positive B cells/plasma cells (blue) in the spleen of an immunized mouse.
Immunofluorescence image showing T cells (red), B cells (green), and IgG1-positive B cells/plasma cells (blue) in the spleen of an immunized mouse.
University Hospital Bonn / D. Baumjohann

Control of the antibody response demonstrated in the laboratory 

The researchers were also able to show that the Tfr cells generated in the laboratory are functionally similar to natural Tfr cells. In cell culture experiments, they suppressed the Tfh-cell-mediated activation of B cells and limited the formation of certain antibody classes.

“Tfr cells are among the most important regulators of the antibody response. The fact that their characteristic properties can now be specifically investigated in cell cultures opens up new possibilities for researching their biological function,” explains corresponding author Prof. Dirk Baumjohann from the Department of Hematology, Oncology, Immuno-Oncology, and Rheumatology at UKB, who is a member of the steering committees of the Cluster of Excellence ImmunoSensation3 and the Transdisciplinary Research Area (TRA) “Life & Health” at the University of Bonn. “This allows us to better understand how antibody responses are regulated and how misdirected immune reactions arise.”

New Tool for Immunological Research

The work provides fundamental insights into the biology of regulatory immune cells and simultaneously offers an important tool for immunological research. The newly developed model will enable researchers to specifically investigate the development and function of Tfr cells and to analyze their role in immune responses in greater detail.


 

Funding:
This work was funded in part by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).

Publication:
Luisa Bach et al.: TGF-β and IL-2 differentially shape T follicular regulatory cell differentiation and stability in vitro. Cellular & Molecular Immunology.
DOI: https://doi.org/10.1038/s41423-026-01440-9

Scientific contact:
Prof. Dr. Dirk Baumjohann
Department of Hematology, Oncology, Immuno-Oncology, and Rheumatology
University Hospital Bonn
Cluster of Excellence ImmunoSensation3 & TRA “Life & Health”, University of Bonn
Phone: 49 (0)228 287 51185
Email: dirk.baumjohann(at)uni-bonn.de 

Press contact:
Julia Weber 
Press Officer and Medical Editor 
Public Relations and Corporate Communication 
University Hospital Bonn 
Phone: (+49) 228 287-10469
Email: julia.weber@ukbonn.de

Related news

News Icon

News categories: Publication

Malaria Causes Permanent Damage to Phagocytes in the Spleen

Macrophages formed in the bone marrow can only assume the function of embryonal phagocytes, or “scavenger cells,” to a certain degree according to a study by the University of Bonn and the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. The researchers have demonstrated that malaria infection causes permanent damage to resident CD163 macrophages in the spleen, which are responsible for cleaning the blood, recycling iron and communicating with other cells involved in the body’s immune response.
View entry
Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry

Back to the news overview